Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053703 · ClinicalTrials.gov registry record · Phase 4
Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 4
- Development phase
- 116
- Enrollment target
NCT00053703 is a Phase 4 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 116 participants.
The verdict
NCT00053703, a Phase 4 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 116 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of risperidone (Risperdal®), olanzapine (Zyprexa®), and molindone (Moban®) for the treatment of children and adolescents with schizophrenia or schizoaffective disorder.
Interventions
- DRUG Risperidone
- DRUG Molindone
- DRUG Olanzapine (enrollment closed in this treatment)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2002-02 |
| Est. Completion | 2007-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00053703
The ClinicalTrials.gov registry entry for NCT00053703 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Risperidone is the first listed.
NCT00053703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00053703 about?
NCT00053703 is a clinical study titled "Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)". This study will evaluate the safety and efficacy of risperidone (Risperdal®), olanzapine (Zyprexa®), and molindone (Moban®) for the treatment of children and adolescents with schizophrenia or schizoaffective disorder.
What is the current status of trial NCT00053703?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 116 participants. The study started on 2002-02. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00053703?
The interventions under investigation include: Risperidone (DRUG), Molindone (DRUG), Olanzapine (enrollment closed in this treatment) (DRUG).
Who is sponsoring clinical trial NCT00053703?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.